To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question

被引：0
|
作者：
Lukasik, Zuzanna [1 ,2 ]
Carron, Philippe [1 ,2 ]
Webers, Casper [3 ,4 ]
机构：
[1] Univ Ghent, Ghent Univ Hosp, Dept Internal Med & Pediat, Ghent, Belgium
[2] VIB Ctr Inflammat Res, Ghent, Belgium
[3] Maastricht Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands
[4] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
来源：
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2023年 / 37卷 / 03期
关键词：
Axial spondyloarthritis; Tapering; Discontinuation; Remission; Therapy; Biological DMARD; SOCIETY CLASSIFICATION CRITERIA; ASAS-EULAR RECOMMENDATIONS; ANKYLOSING-SPONDYLITIS; PSORIATIC-ARTHRITIS; DOSE REDUCTION; PERIPHERAL SPONDYLOARTHRITIS; RHEUMATOID-ARTHRITIS; NON-INFERIORITY; TNF-INHIBITORS; DOUBLE-BLIND;
D O I：
10.1016/j.berh.2023.101869
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页数：17
相关论文
共 50 条
  • [1] Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis
    Wendling, Daniel
    Goupille, Philippe
    IMMUNOTHERAPY, 2020, 12 (12) : 857 - 860
  • [2] An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis
    So, Anthony
    Inman, Robert Davies
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2018, 32 (03): : 453 - 471
  • [3] Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis
    Wendling, Daniel
    Prati, Clement
    IMMUNOTHERAPY, 2017, 9 (03) : 221 - 223
  • [4] Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis: A review of the literature and discussion on current practice
    Webers, Casper
    Nikiphorou, Elena
    Boonen, Annelies
    Ramiro, Sofia
    JOINT BONE SPINE, 2023, 90 (01)
  • [5] Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
    Marona, Jose
    Sepriano, Alexandre
    Rodrigues-Manica, Santiago
    Pimentel-Santos, Fernando
    Mourao, Ana Filipa
    Gouveia, Nelia
    Branco, Jaime Cunha
    Santos, Helena
    Vieira-Sousa, Elsa
    Vinagre, Filipe
    Tavares-Costa, Joao
    Rovisco, Joao
    Bernardes, Miguel
    Madeira, Nathalie
    Cruz-Machado, Rita
    Roque, Raquel
    Silva, Joana Leite
    Marques, Mary Lucy
    Ferreira, Raquel Miriam
    Ramiro, Sofia
    RMD OPEN, 2020, 6 (01):
  • [6] Disease-modifying antirheumatic drugs
    Lambert, David G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2012, 13 (03): : 128 - 130
  • [7] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    STECHER, VJ
    CARLSON, JA
    CONNOLLY, KM
    BAILEY, DM
    MEDICINAL RESEARCH REVIEWS, 1985, 5 (03) : 371 - 390
  • [8] Disease-Modifying Antirheumatic Drugs
    Brasington, Richard
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2009, 34A (02): : 347 - 348
  • [9] Disease-modifying antirheumatic drugs
    Lambert, David G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2009, 10 (01): : 35 - 37
  • [10] Disease-modifying antirheumatic drugs
    Slack, S
    Furst, DE
    DRUGS OF TODAY, 1996, 32 (06) : 463 - 476
12345